









Markets
/
Stocks
/
nasdaq-bhvn
/

Biohaven Ltd

BHVN

View Detailed Chart

15.110USD

+1.750+13.10%

Close 07/17, 16:00（ET）Quotes delayed by 15 min

1.54BMarket Cap

LossP/E TTM



Biohaven Ltd

15.110

+1.750+13.10%

Overview Company Financials

Financials

Intraday

30m

Today

+13.10%

5 Days

+0.53%

1 Month

+3.78%

6 Months

-59.80%

Year to Date

-59.54%

1 Year

-58.36%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 16 analysts

BUY

Current Rating

53.308

Target Price

299.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Biohaven Ltd

BHVN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(3)

Buy(5)

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.261

Neutral

RSI(14)

52.078

Neutral

STOCH(KDJ)(9,3,3)

53.208

Buy

ATR(14)

0.871

High Vlolatility

CCI(14)

86.765

Neutral

Williams %R

11.159

Overbought

TRIX(12,20)

-0.483

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

13.970

Buy

MA10

14.172

Buy

MA20

14.289

Buy

MA50

15.720

Sell

MA100

20.706

Sell

MA200

32.391

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Ticker SymbolBHVN

CompanyBiohaven Ltd

CEODr. Vlad Coric, M.D.

Websitehttps://www.biohaven.com/